Content about Liraglutide

June 27, 2013

Target has ended its relationship with celebrity chef Paula Deen following reports that she used racial slurs, according to published reports.

NEW YORK — Target has ended its relationship with celebrity chef Paula Deen following reports that she used racial slurs, according to published reports.

The Associated Press reported that the Minneapolis-based mass merchandise chain would not replenish its inventory of Paula Deen-branded cookware in its stores or online once the merchandise sold out. Walmart has made a similar announcement.

March 22, 2013

A drug made by Novo Nordisk for Type 2 diabetes produced a 6% loss of weight in a trial of the drug in obese patients, the company said.

BAGSVÆRD, Denmark — A drug made by Novo Nordisk for Type 2 diabetes produced a 6% loss of weight in a trial of the drug in obese patients, the company said.

The Danish drug maker announced results of a 56-week phase-3 trial to investigate the potential of Victoza (liraglutide) to produce and maintain weight loss in overweight and obese patients with Type 2 diabetes.

April 9, 2012

The Food and Drug Administration has approved a change to the label of a Novo Nordisk drug stating that it offers superior blood-sugar control to a competing drug made by Merck, based on results of two clinical studies, Novo Nordisk said Monday.

PRINCETON, N.J. — The Food and Drug Administration has approved a change to the label of a Novo Nordisk drug stating that it offers superior blood-sugar control to a competing drug made by Merck, based on results of two clinical studies, Novo Nordisk said Monday.

March 8, 2012

The market for drugs to treat diabetes — especially Type 2 diabetes — has shown quite a bit of activity lately.

The market for drugs to treat diabetes — especially Type 2 diabetes — has shown quite a bit of activity lately. At the end of January, the Food and Drug Administration approved Bydureon (exenatide), a once-weekly version of the drug Byetta, which was originally developed by Alkermes and subsequently developed further under an alliance between Amylin Pharmaceuticals and Eli Lilly that the two companies formed in 2002. In November 2011, however, Amylin and Lilly terminated their alliance in the wake of an announced diabetes drug partnership between Lilly and Boehringer Ingelheim.

February 3, 2012

Endocrinologists would prescribe a newly approved weekly treatment for Type 2 diabetes to one-fifth of their patients, a new survey showed.

BURLINGTON, Mass. — Endocrinologists would prescribe a newly approved weekly treatment for Type 2 diabetes to one-fifth of their patients, a new survey showed.

October 14, 2011

Two classes of drugs for treating Type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study by Decision Resources.

BURLINGTON, Mass. — Two classes of drugs for treating Type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study by Decision Resources.

The study found that DPP-IV inhibitors and GLP-1 analogues would experience the biggest growth in market share among all drug classes, with a combined market share that will increase from 20% in 2010 to 47% in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

July 8, 2011

Novo Nordisk could be outpacing Eli Lilly and Amylin Pharmaceuticals in the diabetes wars, according to an analysis by healthcare market research firm Decision Resources.

BURLINGTON, Mass. — Novo Nordisk could be outpacing Eli Lilly and Amylin Pharmaceuticals in the diabetes wars, according to an analysis by healthcare market research firm Decision Resources.

June 27, 2011

Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.

SAN DIEGO — Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.

The drug maker found that combining Victoza (liraglutide [rDNA origin] injection) with metformin and/or sulfonylurea helped patients achieve blood-sugar control.

June 17, 2011

A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

BUFFALO, N.Y. — A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

February 2, 2011

A collection of relatively new products helped drive up sales and profits at Novo Nordisk, the Danish drug maker said Wednesday.

BAGSVÆRD, Denmark — A collection of relatively new products helped drive up sales and profits at Novo Nordisk, the Danish drug maker said Wednesday. 

Sales increased by 22% in the North American markets when measured in local currencies, and by 29% when measured in Danish kroner, the company said. Operating profits were $3.5 billion, a 16% increase over 2009.

November 7, 2010

A new study conducted by University of Toronto researchers found that GLP-1 analogues not only...

MISSISSAUGA, Ontario A new study conducted by University of Toronto researchers found that GLP-1 analogues not only help to lower blood-glucose levels, but also have the added benefit of reducing body mass index and waist circumference.

October 24, 2010

Speculation has emerged that Eli Lilly may seek to acquire several other companies in light...

NEW YORK Speculation has emerged that Eli Lilly may seek to acquire several other companies in light of its difficulties winning approval for a long-acting diabetes treatment, according to published reports.

 

October 19, 2010

The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli...

INDIANAPOLIS The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli Lilly and two other companies, the companies said Tuesday.

Lilly, Amylin Pharmaceuticals and Alkermes said the FDA issued them a complete response letter for their application for Bydureon (exenatide), a once-weekly version of the Type 2 diabetes drug Byetta. A complete response letter means that the FDA has completed review of a regulatory application, but issues remain that preclude approval.

 

September 19, 2010

An investigational treatment made by French drug maker Sanofi-Aventis showed “significant” improvement in blood-glucose control...

PARIS An investigational treatment made by French drug maker Sanofi-Aventis showed “significant” improvement in blood-glucose control in patients with diabetes, according to results of a late-stage clinical trial presented at a scientific meeting.

August 4, 2010

African-Americans with Type 2 diabetes taking a Novo Nordisk drug showed improvements in blood sugar,...

June 27, 2010

A recently approved drug for Type 2 diabetes made by Novo Nordisk worked better than...

June 20, 2010

Swiss drug maker Roche has started a risk-mitigation plan in the late-stage clinical trial of...

March 29, 2010

A study published online in the journal Diabetes Care indicated that a once-daily diabetes drug...

March 9, 2010

The market for diabetes drugs will be worth $37 billion by 2018, up from $20...

February 16, 2010

A new injectable Novo Nordisk drug for diabetes is on the shelves, the Danish drug...

February 10, 2010

Diabetes patients may soon find themselves with an expanded range of treatment options....

January 25, 2010

WALTHAM, Mass. A once-weekly treatment for Type 2 diabetes will likely become a popular treatment...

January 25, 2010

The Food and Drug Administration has approved a long-awaited treatment for Type 2 diabetes, the...

January 14, 2010

A member of the trade team of Danish drug maker Novo Nordisk is heading off...

January 13, 2010

Novo Nordisk has started an early-stage clinical trial in the United Kingdom of an investigational...